Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

3.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.9K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.6K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

3.1K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
3.1K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

1.6K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.6K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.1K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EAACI Guidelines on Environmental Science for Allergy and Asthma-Evidence-Based Recommendations for Prevention and Public Health Action to Mitigate the Impact of Pollen Exposure on Respiratory Allergy.

Allergy·2026
Same author

Twelve-Month Real-World Outcomes of Tezepelumab in Severe Asthma: Clinical Remission, Biomarker Changes, and Trigger Burden-A SANI Multicenter Cohort.

Journal of personalized medicine·2026
Same author

Real-world effectiveness of tezepelumab on clinical remission and small airway dysfunction in severe asthma: a 52-week prospective study.

Expert opinion on biological therapy·2026
Same author

Renal-diabetic overlap in pulmonary arterial hypertension.

Heart (British Cardiac Society)·2026
Same author

Small Airway Dysfunction May Mediate the Association Between Body Mass Index and Severe Asthma Exacerbations.

The European respiratory journal·2026
Same author

Use of an Anti-Thymic Stromal Lymphopoietin Agent in Patients With Asthma and Clinically Significant Bronchiectasis: A Case Series.

Chest·2026
Same journal

Implementing acute exacerbations of COPD care bundles: evidence, effectiveness and future directions.

European respiratory review : an official journal of the European Respiratory Society·2026
Same journal

Preclinical human models of primary ciliary dyskinesia.

European respiratory review : an official journal of the European Respiratory Society·2026
Same journal

Bench evidence, bedside uncertainty: hyperoxia, mechanical ventilation and lung injury.

European respiratory review : an official journal of the European Respiratory Society·2026
Same journal

Respiratory support in paediatric patients with bronchiolitis: a systematic review and meta-analysis.

European respiratory review : an official journal of the European Respiratory Society·2026
Same journal

Air pollution-induced airway epithelial barrier dysfunction in COPD: a narrative review of mechanisms and therapeutic implications.

European respiratory review : an official journal of the European Respiratory Society·2026
Same journal

Utilising human cellular models of primary ciliary dyskinesia: a scoping review.

European respiratory review : an official journal of the European Respiratory Society·2026
See all related articles

Related Experiment Video

Updated: Dec 19, 2025

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults
06:11

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults

Published on: February 9, 2022

6.1K

Minimal clinically important difference for asthma endpoints: an expert consensus report.

Matteo Bonini1,2, Marcello Di Paolo1, Diego Bagnasco3

  • 1National Heart and Lung Institute, Royal Brompton Hospital & Imperial College London, London, UK.

European Respiratory Review : an Official Journal of the European Respiratory Society
|June 6, 2020
PubMed
Summary
This summary is machine-generated.

This report reviews the minimal clinically important difference (MCID) for asthma control endpoints. It highlights a need for more research on inflammatory biomarkers for personalized asthma management.

More Related Videos

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

2.9K
Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

43.8K

Related Experiment Videos

Last Updated: Dec 19, 2025

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults
06:11

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults

Published on: February 9, 2022

6.1K
Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

2.9K
Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

43.8K

Area of Science:

  • Pulmonology
  • Clinical Trials
  • Biomarkers

Background:

  • The minimal clinically important difference (MCID) is the smallest change in outcome perceived as beneficial, guiding patient management.
  • Asthma control monitoring relies on various endpoints, but evidence for MCID varies across these measures.

Purpose of the Study:

  • To provide a state-of-the-art review of MCID for asthma control endpoints.
  • To identify unmet needs and guide future research in asthma management.

Main Methods:

  • Expert consensus report synthesizing current literature evidence.
  • Focus on MCID for patient-reported outcomes, lung function, and exercise tolerance in asthma.

Main Results:

  • Established MCID cut-offs exist for patient-reported outcomes, lung function, and exercise tolerance in asthma.
  • Limited data available for MCID of inflammatory biomarkers in asthma control.

Conclusions:

  • Inflammatory biomarkers are crucial for future asthma diagnosis and management, especially with new biologic drugs.
  • Further research on MCID for inflammatory biomarkers is needed to predict treatment response and efficacy.